CTRI/2022/07/043917
Not yet recruiting
Phase 4
Prospective Analysis of safety, effectiveness and compliance of EPO (erythropoietin) therapy by using WEPOX® Dispopen 20,000 IU, A new delivery device, in the management of CKD Anemia - AWAKE
Wockhardt Ltd0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Wockhardt Ltd
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients newly prescribed with WEPOX Dispopen 20000 IU for anemia due to chronic kidney disease (CKD)
- •Patient willing to comply with the protocol and written Informed Consent
Exclusion Criteria
- •Patients who do not meet requirement as per prescribing information of WEPOX Dispopen 20000 IU
- •Pregnant and lactating females
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 4
Safety, effectiveness and compliance study of Wepox dispopen 20000 IU in the management of Anemia due to Chronic kidney disease.CTRI/2023/10/058943Wockhardt Ltd
Recruiting
Not Applicable
A prospective analysis of the efficacy and safety of complete surgery for advanced ovarian, fallopian tubal, primary peritneal cancerJPRN-UMIN000022284School of Medicine, Chiba University100
Not yet recruiting
Not Applicable
A Prospective study of the Safety and Effectiveness of Uterine Artery Embolization for the treatment of Endometriosis (UAE-E) – a Pilot StudyEndometriosisReproductive Health and Childbirth - Other reproductive health and childbirth disordersACTRN12622001301752The Alfred Hospital6
Recruiting
Not Applicable
Retrospective analysis of safety and effectiveness of recombinant thrombomodulin for vascular endothelial syndrome after hematopoietic cell transplantation in children.Pediatric patients who developed vascular endothelial syndrome after hematopoietc cell transplantation.JPRN-UMIN000022640Yokohama City University30
Recruiting
Not Applicable
Prospective evaluation of the safety and efficacy of MR-guided single-fraction stereotactic ablative radiotherapy for unresectable primary or secondary liver tumors - SINGLE SHOT LIVERC22C78.7Malignant neoplasm of liver and intrahepatic bile ductsSecondary malignant neoplasm of liver and intrahepatic bile ductDRKS00027117Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum Grosshadern der LMU München35